Emerging Treatment Options in Inflammatory Bowel Disease

Nov 23, 2020 | health and medicine, Karger Publishers

In Collaboration With

Original Article Reference

This SciPod is a shortened and simplified summary of ‘Emerging Treatment Options in Inflammatory Bowel Disease’, published by Karger Publishers https://doi.org/10.1159/000507782

The complete original works are available at www.karger.com

About this episode

Inflammatory bowel disease (IBD) is a group of gastrointestinal conditions affecting almost 7 million people globally, and this incidence is rising. While treatments have improved over the last century, many patients do not respond sufficiently, especially those with moderate to severe levels of the disease. Novel drugs that restrain the immune system and reduce inflammation are being developed with the hope of improving patient outcomes. Dr Benjamin Misselwitz at Island Hospital of Bern and Bern University and his colleagues have conducted a comprehensive review of the emerging therapies and make recommendations for improving treatment for a wider range of patients.

 

 

 

This work is licensed under a Creative Commons Attribution 4.0 International LicenseCreative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Related episodes

Dr Abayomi Sanusi | Can Faith Institutions Encourage People to Maintain Healthy Blood Pressure?

Dr Abayomi Sanusi | Can Faith Institutions Encourage People to Maintain Healthy Blood Pressure?

High blood pressure, also known as hypertension, is a common and potentially dangerous condition that increases the risk of many severe medical issues, including heart disease, heart attack, stroke, heart failure, and kidney disease. Dr Abayomi Sanusi, a researcher at the University of York, recently carried out a study exploring how faith-based institutions could encourage their community members to adopt healthy behaviours that can reduce hypertension.

Ria Nishikawara | Exploring How to Improve Healthcare for Patients with Fibromyalgia

Ria Nishikawara | Exploring How to Improve Healthcare for Patients with Fibromyalgia

Fibromyalgia is a relatively common and yet poorly understood condition characterised by chronic diffuse pain and stiffness, chronic fatigue, poor sleep and cognitive difficulties. Ria Nishikawara at the University of British Columbia and her collaborators Dr Izabela Schultz, Dr Lee Butterfield, and John Murray, carried out a study exploring the unique healthcare experiences of patients diagnosed with fibromyalgia. Their aim was to determine what patients found most helpful and how the available services could be improved.

Addressing antimalarial drug resistance in Africa to ensure patients can continue to be saved

Addressing antimalarial drug resistance in Africa to ensure patients can continue to be saved

We are pleased to be joined by Dorothy Achu, Regional Malaria Adviser, WHO African Region; Aimable Mbituyumuremyi, Director, National Malaria Control Program, Ministry of Health, Rwanda; Adam Aspinall, Senior Director, Access and Product Management, and George Jagoe, Executive Vice-President Medicines for Malaria Venture. To learn about antimalarial drug resistance in Africa to ensure patients can continue to be saved.

Dr Kerstin Kleinschmidt-Doerr | Could R399E Become a Promising Treatment for Restoring Joints and Relieving Pain in Osteoarthritis?

Dr Kerstin Kleinschmidt-Doerr | Could R399E Become a Promising Treatment for Restoring Joints and Relieving Pain in Osteoarthritis?

Osteoarthritis is a painful and progressive joint disorder that affects hundreds of millions of people worldwide. Typically, the options for treating the condition involve exercise or medication to reduce pain. However, these methods do not target the underlying structural problems in the joints of patients. Recently, researchers have uncovered a genetic susceptibility to osteoarthritis associated with a protein called GDF5, which is involved in skeletal growth and development. Alongside a team of scientists across Europe, Dr Kerstin Kleinschmidt-Doerr at Merck has explored a modified form of the GDF5 protein, named R399E, which showed effects in animal models and in-vitro experiments for treating pain and the underlying structural problems in osteoarthritis.